19 February 2025 - The approval provides another treatment option for breast cancer patients with a PIK3CA mutation, one of the most commonly mutated genes in hormone receptor-positive disease, associated with poor prognosis.

Roche Canada today announced that Health Canada has granted authorisation for Itovebi (inavolisib film-coated tablets) in combination with palbociclib and fulvestrant, for the treatment of adult patients with endocrine-resistant, PIK3CA mutated, hormone receptor positive, human epidermal growth factor receptor 2 negative, locally advanced or metastatic breast cancer, following recurrence on or after completing adjuvant endocrine treatment.

Read Roche press release